Results 81 to 90 of about 683 (135)

Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study. [PDF]

Clin Exp Hypertens, 2016
Handley A, Lloyd E, Roberts A, Barger B.
europepmc   +1 more source

Comparative efficacy and safety of dual-combination vs. triple-combination antihypertensive therapies in hypertensive patients: an updated meta-analysis of randomized controlled trials. [PDF]

Front Pharmacol
Gong Z, Huang L, Long X, Zhang Y.
europepmc   +1 more source

Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. [PDF]

J Hypertens, 2016
White WB, Cuadra RH, Lloyd E, Bakris GL, Kupfer S.   +4 more
europepmc   +1 more source

The Impact of Azilsartan Medoxomil Treatment (Capsule Formulation) at Doses Ranging From 10 to 80 mg: Significant, Rapid Reductions in Clinic Diastolic and Systolic Blood Pressure. [PDF]

J Clin Hypertens (Greenwich), 2017
Perez A, Cao C.
europepmc   +1 more source

Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry. [PDF]

J Clin Hypertens (Greenwich), 2015
Schmieder RE, Potthoff SA, Bramlage P, Baumgart P, Mahfoud F, Buhck H, Ouarrak T, Ehmen M, Senges J, Gitt AK, EARLY Registry Group.   +10 more
europepmc   +1 more source

FDA Drug Repurposing Uncovers Modulators of Dopamine D₂ Receptor Localization via Disruption of the NCS-1 Interaction. [PDF]

J Med Chem
Muñoz-Reyes D, Aguado L, Arroyo-Urea S, Requena C, Pérez-Suárez S, Sánchez-Yepes S, Argerich J, Miró-Rodríguez C, Ulzurrun E, Rodríguez-Martín E, García-Nafría J, Campillo NE, Mansilla A, Sánchez-Barrena MJ.   +13 more
europepmc   +1 more source

New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil. [PDF]

Integr Blood Press Control, 2012
Volpe M, Savoia C.
europepmc   +1 more source

Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. [PDF]

J Clin Hypertens (Greenwich), 2012
Sica D, Bakris GL, White WB, Weber MA, Cushman WC, Huang P, Roberts A, Kupfer S.   +7 more
europepmc   +1 more source

The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry. [PDF]

Trials, 2015
Bramlage P, Schmieder RE, Gitt AK, Baumgart P, Mahfoud F, Buhck H, Ouarrak T, Ehmen M, Potthoff SA, EARLY Registry Group.   +9 more
europepmc   +1 more source

Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. [PDF]

J Hum Hypertens, 2013
Bönner G, Bakris GL, Sica D, Weber MA, White WB, Perez A, Cao C, Handley A, Kupfer S.   +8 more
europepmc   +1 more source